Literature DB >> 15319464

Risk factors for severe hyperbilirubinemia in neonates.

May-Jen Huang1, Ka-Em Kua, Hsiu-Chen Teng, Kung-Sheng Tang, Hui-Wen Weng, Ching-Shan Huang.   

Abstract

The incidence of severe neonatal hyperbilirubinemia is higher in Asians than in whites. A case-control study was designed to investigate the effects of eight known risk factors [breast feeding, ABO incompatibility, premature birth, infection, cephalohematoma, asphyxia, glucose-6-phosphate dehydrogenase (G6PD) deficiency, and variant UDP-glucuronosyltransferase 1A1 (UGT1A1) gene] and a suspicious analog [organic anion transporter 2 (OATP 2) gene] on severe hyperbilirubinemia in Taiwanese neonates. The 72 study subjects and 100 hospital control subjects consisted of neonates with peak serum bilirubin levels > or =342 microM and <256.5 microM, respectively. The PCR-restriction fragment length polymorphism method was applied to detect the UGT1A1, OATP 2, and G6PD genes. The results of multivariate logistic regressions, adjusted for covariates, revealed odds ratios (ORs) of 4.64 [95% confidence interval (CI): 2.25-9.57; p < 0.001], 3.36 (95% CI: 1.54-7.35; p=0.002), and 3.02 (95% CI: 1.30-6.99; p=0.010) for neonates who were fed with breast milk, and carry the variant UGT1A1 gene at nucleotide 211 and the variant OATP 2 gene at nucleotide 388, respectively. The ORs, adjusted for covariates, for the other six risk factors were not statistically significant. The ORs in neonates who had one, two, and three significant risk factors were 8.46 (95% CI: 2.75-34.48; p < 0.001), 22.0 (95% CI: 5.50-88.0; p < 0.001), and 88.0 (95% CI: 12.50-642.50; p < 0.001), respectively. In conclusion, neonates who carry the 211 and 388 variants in the UGT1A1 and OATP 2 genes, respectively, as well as feed with breast milk are at high risk to develop severe hyperbilirubinemia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15319464     DOI: 10.1203/01.PDR.0000141846.37253.AF

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  44 in total

Review 1.  OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies.

Authors:  Megan Roth; Amanda Obaidat; Bruno Hagenbuch
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Bilirubin uridine diphosphate-glucuronosyltransferase variation is a genetic basis of breast milk jaundice.

Authors:  Yoshihiro Maruo; Yoriko Morioka; Hiroshi Fujito; Sayuri Nakahara; Takahide Yanagi; Katsuyuki Matsui; Asami Mori; Hiroshi Sato; Robert H Tukey; Yoshihiro Takeuchi
Journal:  J Pediatr       Date:  2014-03-17       Impact factor: 4.406

3.  Single dose of 50 mg/kg clofibrate in jaundice of healthy term neonates: randomised clinical trial of efficacy and safety.

Authors:  Razieh Fallah; Zia Islami; Saeid Reza Lotfi
Journal:  Indian J Pediatr       Date:  2011-07-22       Impact factor: 1.967

4.  Association of neonatal hyperbilirubinemia in breast-fed infants with UGT1A1 or SLCOs polymorphisms.

Authors:  Hiroko Sato; Toshihiko Uchida; Kentaro Toyota; Tomohiro Nakamura; Gen Tamiya; Miyako Kanno; Taeko Hashimoto; Masashi Watanabe; Kuraaki Aoki; Kiyoshi Hayasaka
Journal:  J Hum Genet       Date:  2014-11-13       Impact factor: 3.172

5.  Incidence of and risk factors for neonatal jaundice among newborns in southern Nepal.

Authors:  Carolyn G Scrafford; Luke C Mullany; Joanne Katz; Subarna K Khatry; Steven C LeClerq; Gary L Darmstadt; James M Tielsch
Journal:  Trop Med Int Health       Date:  2013-09-23       Impact factor: 2.622

6.  Humanized UGT1 Mice, Regulation of UGT1A1, and the Role of the Intestinal Tract in Neonatal Hyperbilirubinemia and Breast Milk-Induced Jaundice.

Authors:  Shujuan Chen; Robert H Tukey
Journal:  Drug Metab Dispos       Date:  2018-08-09       Impact factor: 3.922

7.  Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.

Authors:  Douglas S Hawkins; Yueh-Yun Chi; James R Anderson; Jing Tian; Carola A S Arndt; Lisa Bomgaars; Sarah S Donaldson; Andrea Hayes-Jordan; Leo Mascarenhas; Mary Beth McCarville; Jeannine S McCune; Geoff McCowage; Lynn Million; Carol D Morris; David M Parham; David A Rodeberg; Erin R Rudzinski; Margarett Shnorhavorian; Sheri L Spunt; Stephen X Skapek; Lisa A Teot; Suzanne Wolden; Torunn I Yock; William H Meyer
Journal:  J Clin Oncol       Date:  2018-08-09       Impact factor: 44.544

8.  Effect of genetic variants of bilirubin metabolism on the degree of hyperbilirubinemia in African-American newborns.

Authors:  D L Schutzman; L M Baudhuin; E Gatien; S Ajayi; R J Wong
Journal:  J Perinatol       Date:  2016-12-15       Impact factor: 2.521

9.  Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers.

Authors:  Yu Cheng; Guo Wang; Wei Zhang; Lan Fan; Yao Chen; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2012-07-28       Impact factor: 2.953

10.  UGT1A1 gene variants and clinical risk factors modulate hyperbilirubinemia risk in newborns.

Authors:  P K Tiwari; A Bhutada; R Agarwal; S Basu; R Raman; A Kumar
Journal:  J Perinatol       Date:  2013-11-14       Impact factor: 2.521

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.